Company news

Prelude Therapeutics Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

April 10, 2023

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 14, 2023

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

March 14, 2023

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

February 28, 2023

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

February 8, 2023

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

October 17, 2022

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

September 5, 2022

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 8, 2022

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

May 9, 2022

Prelude Therapeutics Reports Full Year 2021 Financial Results

March 15, 2022

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

March 10, 2022

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

March 8, 2022

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

March 8, 2022

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

November 22, 2021

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

November 11, 2021

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

November 7, 2021

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 6, 2021

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

September 1, 2021

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

August 11, 2021

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors

July 18, 2021

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

May 10, 2021

Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference

May 4, 2021

Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update

March 15, 2021

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

March 2, 2021

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 10, 2021

Prelude Therapeutics Announces Pricing of Upsized Public Offering

January 6, 2021

Prelude Therapeutics Announces Third Quarter 2020 Financial Results

November 9, 2020

Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies

September 29, 2020

Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 28, 2020

Prelude Therapeutics Announces Pricing of Initial Public Offering

September 23, 2020

← Newer news releases

Calls

Decks

The 5 newest of 36 decks. Every deck is listed under its year.